Clinical Trials Browser

Phase 2 × Withdrawn × Pituitary Neoplasms × Clear all

Hemorrhage, Pituitary Neoplasms

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Phase 2 Withdrawn

CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase 2 Withdrawn

Endocrine

Pituitary Neoplasms

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Phase 2 Withdrawn

DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Clinical Trials

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy